Publications in collaboration with researchers from Hospital Universitario Central de Asturias (12)

2023

  1. Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients

    Medicina (Kaunas, Lithuania), Vol. 59, Núm. 8

2020

  1. Comparative study between two european inception cohorts of patients with early systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 925-932

2018

  1. Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity

    Lupus, Vol. 27, Núm. 10, pp. 1718-1722

  2. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort

    Lupus, Vol. 27, Núm. 14, pp. 2253-2261

  3. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study

    Arthritis Care and Research, Vol. 70, Núm. 4, pp. 582-591

2017

  1. Características clínicas al diagnóstico de una cohorte prospectiva de pacientes con lupus eritematoso sistémico atendidos en servicios de Medicina Interna españoles: estudio RELES

    Revista Clinica Espanola, Vol. 217, Núm. 1, pp. 7-14

  2. Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE)

    Clinical and Experimental Rheumatology, Vol. 35, pp. S40-S47

  3. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 35, pp. S98-S105

2016

  1. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

    Lupus Science and Medicine, Vol. 3, Núm. 1

  2. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

  3. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476